Oncology Cardiology / Cardiovascular Respiratory / COPD / Asthma Infectious Disease Gastroenterology Diabetes / Metabolic Neurology Rheumatology Women's Health Mental Health / Psychiatry Dermatology Rare Diseases Men's Health
Trial Radar • ClinicalTrials.gov • Registry-linked

Trial Radar

1963 clinical trials with phase, status, specialty and registry links, summarised for rapid clinical review.

1963 recruiting AI clinical summaries
Explore Trial Collections Follow research updates
All Phases Phase I Phase II Phase III Phase IV
Therapeutic Area: All Cardiology / Cardiovascular Dermatology Diabetes / Metabolic Gastroenterology Haematology Infectious Disease Men's Health Mental Health / Psychiatry Nephrology Neurology Oncology Rare Diseases
🔬
Trial Radar

Clinical Trial Intelligence

● Recruiting Phase II Diabetes / Metabolic
A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide
What is being tested: LY3457263, a novel investigational agent, is being evaluated as an add-on therapy to semaglutide or tirzepatide in patients whose blood…
17 Apr 2026 NCT06897475
● Recruiting Phase IV Diabetes / Metabolic
A Study of Tirzepatide (LY3298176) Compared With Standard of Care in Adult Participants With Obesity and Without Diabetes (SURMOUNT-REAL UK)
What is being tested: Tirzepatide (a dual GIP/GLP-1 receptor agonist) versus standard obesity care in a real-world UK setting, measuring weight loss and type…
17 Apr 2026 NCT07247084
● Recruiting Diabetes / Metabolic
Real-World Study of Patients With Type 1 Diabetes Treated With Teplizumab as Part of Managed Access Programs (MAPs)
What is being tested: Teplizumab, an anti-CD3 monoclonal antibody, is being evaluated in real-world clinical practice through managed access programs to assess its effectiveness…
17 Apr 2026 NCT07457580
● Recruiting Cardiology / Cardiovascular
Post-Market Celect Platinum Vena Cava Filter and Gunther Tulip Retrieval Set Study
What is being tested: Real-world safety and performance data collection for two vena cava filter devices—the Celect Platinum Filter Sets and the Günther Tulip…
17 Apr 2026 NCT05881798
● Recruiting Phase III Cardiology / Cardiovascular
Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease
What is being tested: Orforglipron, a once-daily treatment, is being evaluated for its efficacy and safety in managing Fontaine II peripheral arterial disease (symptomatic…
17 Apr 2026 NCT07223593
● Recruiting Phase III Cardiology / Cardiovascular
A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event
What is being tested: AZD0780, an oral PCSK9 inhibitor, is being evaluated in a Phase III randomized controlled trial to assess its efficacy in…
17 Apr 2026 NCT07000357
● Recruiting Phase III Cardiology / Cardiovascular
A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)
What is being tested: Orforglipron (LY3502970), a GLP-1 receptor agonist, is being evaluated for its effects on cardiovascular outcomes compared to placebo over approximately…
17 Apr 2026 NCT07241390
● Recruiting Cardiology / Cardiovascular
BradycArdia paCemaKer With AV Interval Modulation for Blood prEssure treAtmenT
What is being tested: A novel atrioventricular interval modulation (AVIM) algorithm integrated into dual-chamber pacemakers to evaluate its safety and effectiveness as a potential…
17 Apr 2026 NCT06059638
● Recruiting Phase I Oncology
A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9
What is being tested: BNT329, an investigational drug designed to target CA19-9-expressing advanced solid tumors, with primary focus on establishing safety profile and optimal…
17 Apr 2026 NCT07186842
● Recruiting Oncology
SPECTA: Screening Cancer Patients for Efficient Clinical Trial Access
What is being tested: SPECTA is a standardized biobank platform collecting high-quality annotated biological samples, imaging data, operative records, and patient-reported outcomes from cancer…
17 Apr 2026 NCT02834884
● Recruiting Phase I Oncology
A First-in-human Study to Learn How Safe BAY 3713372 is and How it Works in Participants With MTAP-deleted Solid Tumors
BAY 3713372 is a novel PRMT5 inhibitor being tested in a first-in-human trial to treat MTAP-deleted solid tumors, designed to selectively target cancer cells…
17 Apr 2026 NCT06914128
● Recruiting Phase III Oncology
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
Intervention being tested: Vepugratinib (LY3866288), a novel therapeutic agent, is being evaluated against placebo in a randomised controlled trial to assess safety, tolerability, and…
17 Apr 2026 NCT07218380
● Recruiting Phase III Oncology
Study Comparing Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care Chemotherapy for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor Acute Lymphoblastic Leukemia
A new drug combination tested against standard treatment in older adults with newly diagnosed acute lymphoblastic leukaemia.
16 Apr 2026 NCT04994717
active not recruiting Phase III Dermatology
Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant
Elranatamab injections compared to lenalidomide tablets for newly diagnosed myeloma patients after stem cell transplant.
16 Apr 2026 NCT05317416
active not recruiting Phase III
Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL)
New drug combination (sonrotoclax plus zanubrutinib) tested against standard treatment (venetoclax plus obinutuzumab) for chronic lymphocytic leukaemia.
16 Apr 2026 NCT06073821
● Recruiting Gastroenterology
Study of an Intrathecal Port and Catheter System for Subjects With Spinal Muscular Atrophy
Implanted spinal port safely delivers nusinersen treatment to spinal muscular atrophy patients over 12 months.
16 Apr 2026 NCT05866419
● Recruiting Phase III
Randomized Study in Children and Adolescents With Migraine: Acute Treatment
Researchers tested whether a new migraine drug (BHV-3000) works better than placebo for treating severe migraines in young people.
16 Apr 2026 NCT04649242
● Recruiting Phase III
Phase 3, Open-label, Single-dose Study of CSL222 in Adolescent Male Subjects (≥ 12 to < 18 Years of Age) With Severe or Moderately Severe Hemophilia B
CSL222 Trial Summary CSL222 gene therapy tested in teenage boys with moderate-to-severe hemophilia B for safety, tolerability, and effectiveness.
16 Apr 2026 NCT07080905
active not recruiting Phase III Oncology
A Study to Learn More About How Well Elinzanetant Works and How Safe it is Compared to Placebo for the Treatment of Hot Flashes Caused by Anti-cancer Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast Cancer
Elinzanetant reduces hot flashes from cancer therapy in breast cancer patients better than placebo.
16 Apr 2026 NCT05587296
active not recruiting Phase III Oncology
Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib
Patients benefiting from olaparib in previous cancer trials can continue receiving it under this extension study.
16 Apr 2026 NCT04421963
● Recruiting Phase III
Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)
What is being tested: Ravulizumab, a complement C5 inhibitor, is being evaluated against placebo for its ability to reduce proteinuria and slow decline in…
16 Apr 2026 NCT06291376
● Recruiting Phase III Respiratory / COPD / Asthma
A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn’s Disease (CD)
What is being tested: Long-term safety and efficacy of vedolizumab (an anti-α4β7 integrin monoclonal antibody) as maintenance therapy in paediatric patients with moderate-to-severe ulcerative…
16 Apr 2026 NCT05442567
● Recruiting Phase III Oncology
JoLT-Ca Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) for Lung Cancer
What is being tested: A comparison of stereotactic ablative radiotherapy (SAbR) versus surgical sublobar resection (SR) to determine which approach provides superior survival outcomes…
16 Apr 2026 NCT02468024
● Recruiting Phase III Oncology
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
What is being tested: Elranatamab, a bispecific antibody targeting BCMA and CD3, is being evaluated against standard treatments in relapsed/refractory multiple myeloma (RRMM) patients…
16 Apr 2026 NCT06152575
● Recruiting Phase I Cardiology / Cardiovascular
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
Treatment Being Tested: Sonrotoclax (BGB-11417), a BCL2 inhibitor, evaluated as monotherapy and combined with established myeloma regimens (carfilzomib, daratumumab, or pomalidomide) in relapsed/refractory multiple…
16 Apr 2026 NCT04973605
● Recruiting Phase III Cardiology / Cardiovascular
Lp(a) Lowering Study of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Elevated Lp(a) and Established ASCVD
What is being tested: Pelacarsen (TQJ230), an antisense oligonucleotide therapy designed to lower lipoprotein(a) (Lp(a)), is being evaluated for efficacy and safety in patients…
16 Apr 2026 NCT06813911
● Recruiting Phase III Oncology
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
What is being tested: Sacituzumab tirumotecan (MK-2870), an antibody-drug conjugate, as maintenance therapy either alone or combined with bevacizumab, compared to standard of care…
16 Apr 2026 NCT06824467
● Recruiting Phase III Oncology
Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer
What is being tested: T-DXd (trastuzumab deruxtecan) combined with rilvegostomig or as monotherapy, compared against standard-of-care gemcitabine plus cisplatin with durvalumab in treatment-naïve patients…
16 Apr 2026 NCT06467357
● Recruiting Oncology
Breast Cancer Evolution During Neoadjuvant Systemic Therapy
What is being tested: BELIEVE is a translational study collecting breast cancer tissue, blood, and imaging samples from patients receiving neoadjuvant systemic therapy (chemotherapy,…
16 Apr 2026 NCT06681064
● Recruiting Phase III Oncology
A Study of BGB-16673 Compared to Investigator’s Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors
What is being tested: BGB-16673, a novel therapeutic agent, is being evaluated against standard investigator-selected treatments (idelalisib, bendamustine, or venetoclax—each combined with rituximab) in…
16 Apr 2026 NCT06846671
● Recruiting Oncology
Study of Ultomiris® (Ravulizumab) Safety in Pregnancy
What is being tested: Ultomiris® (Ravulizumab), a C5 complement inhibitor, is being evaluated for safety outcomes in pregnant women and their offspring, including maternal…
16 Apr 2026 NCT06312644
● Recruiting Phase III Oncology
Study to Evaluate INCB123667 Versus Investigator’s Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
What is being tested: INCB123667, a targeted therapy, is being compared against standard chemotherapy regimens in patients with platinum-resistant ovarian cancer specifically selected for…
16 Apr 2026 NCT07214779
● Recruiting Phase III Oncology
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
What is being tested: Palazestrant (an oral selective oestrogen receptor degrader) combined with ribociclib (CDK4/6 inhibitor) versus the standard treatment of letrozole (aromatase inhibitor)…
16 Apr 2026 NCT07085767
active not recruiting Phase III Oncology
Study to Continue Treatment With Darolutamide in Patients Who Have Been Participating in Previous Darolutamide Studies Supported by Bayer
Ongoing access to darolutamide for prostate cancer patients who benefited from previous trials, with continued monitoring.
15 Apr 2026 NCT04464226
active not recruiting
SAPIEN 3 Ultra System PMCF
Edwards SAPIEN 3 Ultra valve reduces symptoms in patients with severe aortic stenosis, confirming safety and effectiveness in real-world use.
15 Apr 2026 NCT04555967
● Recruiting Phase III Neurology
A Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS)
DEEP SEA Study Summary LP352 tested against placebo to reduce seizures in children and adults with Dravet syndrome over 24 months.
15 Apr 2026 NCT06660394
active not recruiting Phase II
A Study of Intrathecal SHP611 in Children With Metachromatic Leukodystrophy
Spinal fluid injections of SHP611 tested to slow movement decline in children with metachromatic leukodystrophy.
15 Apr 2026 NCT03771898
active not recruiting Phase IV Oncology
RADIANT: A Study of Radium-223 Dichloride (Xofigo) vs Enzalutamide or Abiraterone (ARPIs, Androgen Receptor Pathway Inhibitors) in Patients With Prostate Cancer That Has Spread to the Bones (mCRPC, Metastatic Castration-Resistant Prostate Cancer)
Trial comparing radium-223 with standard hormone therapy for advanced prostate cancer spread to bones.
15 Apr 2026 NCT04597125
● Recruiting Phase II Oncology
Inobrodib, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma
Inobrodib combined with pomalidomide and dexamethasone shows promise in treating multiple myeloma that resists standard therapies.
15 Apr 2026 NCT07096778
● Recruiting Phase I Neurology
First in Human Safety and Ease of Use Assessment of 400mg Progesterone Callavid in Women With Luteal Phase Insufficiency
Early-stage trial testing safety and user experience of new vaginal progesterone device versus standard pessaries in women with luteal phase insufficiency.
15 Apr 2026 NCT07136922
● Recruiting Phase II Oncology
A Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients With ctDNA-positive, Resected Stage II (High Risk) and Stage III Colorectal Cancer
Treatment being tested: RO7198457 (an investigational targeted therapy) is being compared against watchful waiting in patients with detectable circulating tumor DNA (ctDNA) following surgical…
15 Apr 2026 NCT04486378
● Recruiting Phase I Oncology
Investigating SX-682 in Combination With Apalutamide in Metastatic Castration-resistant Prostate Cancer
Treatment being tested: SX-682 (a CXCR4 inhibitor) combined with apalutamide (an androgen receptor inhibitor) in men with metastatic castration-resistant prostate cancer, aiming to overcome…
15 Apr 2026 NCT07002320
● Recruiting Phase I Oncology
A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer
What is being tested: A dual immunotherapy combination of BNT324 (B7-H3 targeted antibody-drug conjugate) and BNT327 (PD-L1/VEGF bispecific antibody) to evaluate efficacy and safety…
15 Apr 2026 NCT06892548
● Recruiting Oncology
Real-world Evaluation of Patient Outcomes and Experiences With Ribociclib Early Adopters.
What is being tested: A real-world evaluation of ribociclib (CDK4/6 inhibitor) effectiveness, persistence, safety profile, treatment patterns, and patient-reported outcomes including adherence, satisfaction, and…
15 Apr 2026 NCT07243002
● Recruiting Respiratory / COPD / Asthma
Development of a Database to Investigate Digital and Blood-Based Biomarkers and Their Relationship to Tau and Amyloid PET Imaging in Older Participants Who Are Cognitively Normal (CN), Have Mild Cognitive Impairment (MCI), or Have Mild-to-Moderate AD Dementia
What is being tested: Digital biomarkers and blood-based biomarkers are being evaluated for their ability to correlate with tau and amyloid PET imaging findings,…
15 Apr 2026 NCT06584357
● Recruiting Phase I Neurology
An Open-label Study to Investigate ECUR-506 in Male Babies Less Than 9 Months of Age With Neonatal Onset OTC Deficiency
Treatment being tested: ECUR-506, a novel therapeutic intervention for neonatal-onset Ornithine Transcarbamylase (OTC) deficiency, the most common urea cycle disorder caused by defective ammonia…
15 Apr 2026 NCT06255782
● Recruiting Phase II Diabetes / Metabolic
A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Chronic Kidney Disease
Intervention tested: Vicadrostat (a novel selective aldosterone synthase inhibitor) combined with empagliflozin (an SGLT2 inhibitor) in adults with progressive chronic kidney disease, building on…
15 Apr 2026 NCT06926660
● Recruiting Phase II Oncology
Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer
What is being tested: Autologous LN-145, a tumor-infiltrating lymphocyte (TIL) therapy administered to patients with metastatic non-small-cell lung cancer (NSCLC) in a phase 2…
15 Apr 2026 NCT04614103
● Recruiting Phase II Oncology
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
What is being tested: BNT327 (an investigational agent) combined with chemotherapy and other experimental drugs in first-line treatment of non-small cell lung cancer (NSCLC),…
15 Apr 2026 NCT06712316
● Recruiting Phase II Diabetes / Metabolic
Efficacy of KL1333 in Adult Patients With Primary Mitochondrial Disease
What is being tested: KL1333, a novel therapeutic agent, is being evaluated for its efficacy in reducing disease manifestations of primary mitochondrial disease (PMD),…
15 Apr 2026 NCT05650229